Product Description
A previous study with a vaccine candidate based on the low seroprevalent adenoviruses 26 and 35 (Ad26 and Ad35) was shown to provide protection against homologous Ebola Zaire challenge in non human primates (NHP) if applied in a prime-boost regimen
Mechanisms of Action: TNF Inhibitor, IL1B Inhibitor
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Oral, Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Crucell Holland BV
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20171626 |
CTR20171626 | P1 |
Active, not recruiting |
Alzheimer Disease |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20160808 |
CTR20160808 | P1 |
Active, not recruiting |
Alzheimer Disease |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/07/2026 |
News Article |
Acronis Launches MDR by Acronis TRU to Provide 24/7 Threat Detection and Response for MSPs |
|
02/11/2025 |
News Article |
Abcourt Intersects 1.2 g/t Gold over 23.5 Meters Directly Below Cartwright Stripping on its Flordin Property in the Lebel-sur-Quévillon Area |
|
10/14/2024 |
News Article |
Discover the GRAB (GrabWay) Listing on XT Exchange |
|
05/01/2023 |
News Article |
Quarterly Activities Report |